GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: T.14 is a dual action compound that acts as an inhibitor of VEGFR2 (KDR) and the PD-L1 protein [1]. Functionally it has antiangiogenic and immunomodulator actions, that are indicative of experimental anti-tumour potential.
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| T.14 inhibits VEGFR2 kinase activity and resulting tube formation of endothelial cells, plus it enhances the effect of BMS-8 (PubChem CID 117941742) which is a small molecule protein-protein interaction inhibitor that targets the immune inhibitory interaction between PD-1 and its ligand PD-L1 [1-2]. T.14 inhibits VEGFR2 phosphorylation in A549 cells by 82% (sorafenib in the same assay inhibits by 84%), and inhibits HMEC-1 (endothelial) cell tube formation at 100 nM (sorafenib in the same assay requires 10 μM to achieve the same effect). It reduces free PD-L1 by 75%, compared to BMS-8 which reduces free PD-L1 by 32%. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||